Home › FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment
 

Keywords :   


FDA Approves Perjeta For Neoadjuvant Breast Cancer Treatment

2013-10-02 06:33:29| drugdiscoveryonline News Articles

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer

Tags: treatment cancer breast breast cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10Hurricane Milton Potential Storm Surge Flooding Map
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10Hurricane Milton Graphics
07.10Hurricane Leslie Forecast Discussion Number 19
07.10Hurricane Milton Forecast Discussion Number 7
07.10Hurricane Milton Wind Speed Probabilities Number 7
07.10Hurricane Leslie Graphics
07.10Hurricane Milton Forecast Advisory Number 7
More »